Chemical Component Summary

Identifiers 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
Formula C15 H10 O5
Molecular Weight 270.237  g/mol
Isomeric SMILES Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O
InChI InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H

Chemical Details

Formal Charge 0
Atom Count 30
Chiral Atom Count 0
Chiral Atoms n/a
Bond Count 32
Aromatic Bond Count 18
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB01645   (Stereoisomeric match)
Name Genistein
Groups investigational
Description An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. [Wikipedia] Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. [1] Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. [Wikipedia]
  • 4',5, 7-Trihydroxyisoflavone
  • 5,7,4'-Trihydroxyisoflavone
  • Genisteol
  • Genisterin
Brand Names
  • Prunetol
  • Sophoricol
Affected Organism
  • Humans and other mammals
  • Helminthic Microorganisms
  • Parasitic nematodes and other roundworms
Indication Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.
Mechanism of action Genistein may inhibit cancer cell growth by blocking enzymes required for cell growth. Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women. [1] In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea. [1]
  • Protein Kinase Inhibitors
  • Anticarcinogenic Agents
  • Phytoestrogens
CAS number 446-72-0
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682